Preventive Services for Non-Grandfathered (PPACA) Plans: Immunizations - CAM 109HB
Description
The U.S. Patient Protection and Affordable Care Act (PPACA) was passed by Congress and signed into law by the president in March 2010. The preventive services component of the law became effective Sept. 23, 2010. A component of the law was a requirement that all “non-grandfathered” health insurance plans are required to cover those preventive medicine services given an “A” or “B” recommendation by the U.S. Preventive Services Task Force (USPSTF).
Plans are not required to provide coverage for the preventive services if they are delivered by out-of-network providers.
Task force recommendations are graded on a five-point scale (A – E), reflecting the strength of evidence in support of the intervention. Grade A: There is good evidence to support the recommendation that the condition be specifically considered in a periodic health examination. Grade B: There is fair evidence to support the recommendation that the condition be specifically considered in a periodic health examination. Grade C: There is insufficient evidence to recommend for or against the inclusion of the condition in a periodic health examination, but recommendations may be made on other grounds. Grade D: There is fair evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination. Grade E: There is good evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.
Those preventive medicine services listed as Grade A & B recommendations are covered without cost sharing (i.e., deductible, coinsurance or copay) by Health Plans for appropriate preventive care services provided by an in-network provider. If the primary purpose for the office visit is for other than Grade A or B USPSTF preventive care services, deductible, coinsurance or copay may be applied.
Services are typically included as part of a normal wellness visit; the appropriate office visit code should be used. Evaluation and Management codes for preventive services 99381 – 99397 will always be considered preventive. CPT Codes 99401 – 99404, when used to designate a preventive service, must have the applicable wellness/preventive diagnosis code as the primary reason for the visit.
When the primary purpose of the service is the delivery of an evidence-based service in accordance with a U.S. Preventive Services Task Force A or B rating in effect and other preventive services identified in preventive services mandates (legislative or regulatory), the service may be billed with Modifier ‘-33.'
TRAVEL IMMUNIZATIONS ADDITIONAL INFORMATION:
Immunizations that are specific to travel (e.g., typhoid, yellow fever, cholera, plague and Japanese encephalitis virus) are not required by PPACA and are excluded from coverage.
NOTE: THIS POLICY APPLIES ONLY TO NON-GRANDFATHERED PLANS.
Background
The ACIP develops recommendations on how to use vaccines to control disease in the United States. The recommendations include the age(s) when the vaccines should be given, the number of doses needed, the amount of time between doses and precautions and contraindications.
Professional organizations that work with the ACIP to develop the annual childhood and adult schedules include the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG) and the American College of Physicians (ACP).
The Committee's recommendations are forwarded to CDC’s director for approval. Once the ACIP recommendations have been reviewed and approved by the CDC director and the U.S. Department of Health and Human Services, they are published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The MMWR publication represents the final and official CDC recommendations for immunization of the U.S. population.
Each year, the Advisory Committee on Immunization Practices (ACIP) publishes immunization schedules for persons age birth through 18 years. These schedules summarize recommendations for routine vaccines for children age 18 years and younger.
The recommended immunization schedules for persons age birth through 18 years and the catch-up immunization schedule have been approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, the American Academy of Family Physicians and the American College of Obstetricians and Gynecologists.
Policy
The following immunizations are considered MEDICALLY NECESSARY when given in accordance with ACIP guidelines:
An immunization is considered NOT MEDICALLY NECESSARY if it does not meet Vaccine Policy requirements for FDA labeling (including age and/or gender limitations) and if it does not have definitive ACIP recommendations published in the CDC’s Morbidity and Mortality Weekly Report (MMWR).
• Age Group column: This column is provided for informational use only. For purposes of this document: Adult means age 18 years and up; pediatric means age 0 – 18 years.
• Benefit Limits column: Benefit Limits in bold text are from FDA labeling and ACIP recommendations. Codes that indicate “For applicable age, see code description” are limited to the age(s) listed in the code description.
PREVENTIVE IMMUNIZATIONS
These codes do not have a diagnosis code requirement for preventive benefits to apply.
PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply. |
|||||
Category: | Code(s): | Description: | Age Group: | Benefit Limits: Age/Other | |
Immunization administration Preventive when included as part of a preventive immunization. |
90460 | Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | Pediatric | For applicable age see code description | |
90461 | Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | Pediatric | For applicable age see code description | ||
90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid) | Both | - | ||
90472 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | Both | - | ||
90473 | Immunization administration by intranasal or oral route; one vaccine (single or combination vaccine/toxoid) | Both | - | ||
90474 | Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | Both | - | ||
G0008 | Administration of influenza virus vaccine | Both | - | ||
G0009 | Administration of pneumococcal vaccine | Both | - | ||
G0010 | Administration of hepatitis B vaccine | Both | - | ||
Meningococcal | 90619 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use | Both | - |
|
90620 | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use | Both | Benefit Limit: Age 10 and up |
||
90621 | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use | Both | Benefit Limit: Age 10 and up |
||
90623 (effective 10/20/2023) | Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use | Allowed for 10-25 years old. | Allowed only for members between 10-25 years of age | ||
90644 | Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 2 – 15 months of age, for intramuscular use | Pediatric | For applicable age see code description. | ||
90733 | Meningococcal polysaccharide vaccine , serogroups A, C, Y, W-135, quadrivalent (MPSV4) for subcutaneous use | Both | |||
90734 | Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MenACWY), for intramuscular use | Both | |||
Hepatitis A | 90632 | Hepatitis A vaccine (HepA), adult dosage, for intramuscular use | Adult | For applicable age see code description. | |
90633 | Hepatitis A vaccine (HepA), pediatric/ adolescent dosage-2 dose schedule, for intramuscular use | Pediatric | For applicable age see code description. | ||
90634 | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use | Pediatric | For applicable age see code description. | ||
90636 | Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use | Adult | For applicable age see code description. | ||
Haemophilus influenza b (Hib): | 90645 | Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use | Both | - | |
90646 | Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use | Both | - | ||
90647 | Haemophilus influenzae b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use | Both | - | ||
90648 | Haemophilus influenzae b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use | Both | - | ||
Human papillomavirus (HPV) | 90649 | Human Papilloma virus vaccine, types 6, 11, 16, 18, quadrivalent (HPV4), 3 dose schedule, for intramuscular use |
Both | Benefit Limit: Ages 9 – 26yrs. Ends on 27th birthday. | |
90650 | Human Papilloma virus vaccine, types 16, 18, bivalent (HPV2), 3 dose schedule, for intramuscular use | Both | Benefit Limit: Females, ages 9 – 26 yrs. Ends on 27th birthday. This vaccine is not covered for males. |
||
90651 | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | Both | Benefit Limit: Ages 9 – 26yrs. Ends on 27th birthday.COV | ||
COVID | 0121A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | ||
0141A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0142A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0151A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0171A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | Age 6 months and above | |||
0172A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | Age 6 months and above | |||
0124A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0134A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0144A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0154A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0164A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0173A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
0174A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Age 6 months and above | |||
90480 (effective 09/11/2023) | Immunization administration by intramuscular injection of severe acute respiratory syndrom cornavirus 2 (SARS-CO V-2) (coronavirus disease (COVID-19) vaccine, single dose | All ages | |||
91300 (terminated as of 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease(COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use. | 6 years of age and greater | |||
91301 (terminated as of 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use | 6 years of age and greater | |||
91302 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use | Age 6 months and above | |||
91303 (terminated as of 06/01/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use | 6 years of age and greater | |||
91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use. | Age 6 months and above | |||
91305 (terminated as of 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 6 years of age and greater | |||
91306 (terminated on 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | 6 years of age and greater | |||
91307 (terminated as of 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 6 years of age and greater | |||
91308 (terminated as of 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV -2) (coronavirus disease (COVID -19)) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | 6 years of age and greater | |||
91309 (terminated as of 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA, LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | 6 years of age and greater | |||
91311 (terminated as of 04/18/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV -2) (coronavirus disease (COVID -19)) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | 6 years of age and greater | |||
91312 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | Age 6 months and above | |||
91313 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use | Age 6 months and above | |||
91314 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | Age 6 months and above | |||
91315 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Age 6 months and above | |||
91316 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL10 mcg/0.2 mL dosage, for intramuscular use | Age 6 months and above | |||
91317 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Age 6 months and above | |||
91318 (effective 09/11/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.23 mL dosage, tris-sucrose formulation, for intramuscular use | 6 months- 4 years | |||
91319 (effective 09/11/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, 10 mcg/0.23 mL dosage, tris-sucrose formulation, for intramuscular use | 5 years through 11 years | |||
91320 (effective 09/11/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 12 years and older | |||
91321 (effective 09/11/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use | 6 months through 11 years | |||
91322 (effective 09/11/2023) | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular us | 12 years and older | |||
Respiratory Syncytial Virus | 90679 (effective 05/05/2023) | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use | Age 60 years and older | ||
90380 (effective 07/17/2023) | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use. | Neonate-24 months of age (effective 07/17/2023) | |||
90381 (effective 07/17/023) | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1mL dosage, for intramuscular use. | Neonate-24 months of age (effective 07/17/2023) | |||
Seasonal Influenza (‘flu’) Note: Additional new seasonal flu immunization codes that are recently FDA-approved, but are not listed here, may be eligible for preventive benefits as of the FDA approval date. |
90630 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use | Both | - | |
90653 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use | Both | - | ||
90654 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use | Adult | Benefit Limit: 18 years – 64 years. Ends on 65th birthday. | ||
90655 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, when administered to children 6 – 35 months of age, for intramuscular use | Pediatric | For applicable age see code description. | ||
90655 (effective 1/1/2017) | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use | both | |||
90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, when administered to individuals 3 years and older, for intramuscular use | Both | For applicable age see code description. | ||
90656 (effective 1/1/2017) | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | Both | |||
90657 | Influenza virus vaccine, trivalent(IIV3), split virus, when administered to children 6 – 35 months of age, for intramuscular use | Pediatric | For applicable age see code description. | ||
90657 (effective 1/1/2017) | Influenza virus vaccine, trivalent(IIV3), split virus, 0.25 mL dosage, for intramuscular use | both | |||
90658 | Influenza virus vaccine, trivalent (IIV3), split virus, when administered to individuals 3 years of age and older, for intramuscular use | Both | For applicable age see code description. | ||
90658 (effective 1/1/2017) | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use | Both | |||
90660 | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use | Both | Benefit Limit: Ages 2 – 49 Years. Ends on 50th birthday | ||
90661 | Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use | Adult | Benefit Limit: Ages 18 years and up |
||
90661 (effective 1/1/2017) | Influenza virus vaccine trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | Adult |
|
||
90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | Adult | Benefit Limit: Ages 65 years and up |
||
90664 | Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use | Both | Benefit Limit: Ages 2 – 49 Years. Ends on 50th birthday. | ||
90666 | Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use | Both | - | ||
90667 | Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use | Both | - | ||
90668 | Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use | Both | - | ||
90672 | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | Both | Benefit Limit: Ages 2 – 49 Years. Ends on 50th birthday. | ||
90673 | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use | Adult | Benefit Limit: Ages 18 – 49 Years. Ends on 50th birthday. | ||
90674 (effective 1/1/2017) | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subnit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | Adult | |||
90685 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, when administered to children 6 – 35 months of age, for intramuscular use | Pediatric | For applicable age see code description. | ||
90682 (effective 1/01/2018) | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use | Both | |||
90685 (effective 1/1/2017) | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | Both | |||
90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, when administered to individuals 3 years of age and older, for intramuscular use | Both | For applicable age see code description. | ||
90686 (effective 1/1/2017) | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | Both | |||
90687 | Influenza virus vaccine, quadrivalent (IIV4), split virus, when administered to children 6 – 35 months of age, for intramuscular use | Pediatric | For applicable age see code description. | ||
90687 (effective 1/1/2017) | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use | Both | |||
90688 | Influenza virus vaccine, quadrivalent (IIV4), split virus, when administered to individuals 3 years of age and older, for intramuscular use | Both | For applicable age see code description. | ||
90688 (effective 1/1/2017) | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | Both | |||
90689 (effective 01/01/2019) | Influenza virus vaccine, quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use |
Both | |||
90694 | INFLUENZA VIRUS VACCINE, QUADRIVALENT (AIIV4), INACTIVATED, ADJUVANTED, PRESERVATIVE FREE, 0.5 ML DOSAGE, FOR INTRAMUSCULAR USE |
Both | |||
90756 (effective 1/1/2018) | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use TOS Code: V |
Adult | |||
Q2034 | Influenza virus vaccine, split virus, for intramuscular use (Agriflu) | Adult | Benefit Limit: Ages 18 years and up |
||
Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA) | Both | For applicable age see code description. | ||
Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL) | Both | For applicable age see code description. | ||
Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLUVIRIN) | Both | For applicable age see code description. | ||
Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone) | Both | For applicable age see code description. | ||
Q2039 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified) | Both | For applicable age see code description. | ||
Pneumococcal polysaccharide (PPSV23) | 90732 | Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use | Both | For applicable age see code description. | |
Pneumococcal conjugate | 90669 | Pneumococcal conjugate vaccine, 7 valent (PCV7), for intramuscular use | Pediatric | Benefit Limit: Age 0 – 5 yrs. Ends on 6th birthday | |
90670 | Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | Both | - | ||
90671 (effective 12/06/2021) | Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use | Both | |||
90677 (effective 12/15/2021) | Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | Both | |||
90684 (effective 06/17/2024) | Pneumococcal conjugate vaccine, 21 valent (PCV), for intramuscular use | Adults | |||
S0195 | Pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine | Pediatric | For applicable age see code description. | ||
Respiratory Syncytial Virus | 96380 (effective 10/06/2023) | Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional | 24 months of age and younger | ||
96381 (effective 10/06/2023) | Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection | 24 months of age and younger | |||
90683 (effective 5/31/2024) | Respiratory syncytial virus vaccine, mRNA Lipid nanoparticles, for intramuscular use. | Adults, 60 years of age and greater | |||
90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use. | Adults | Benefit limits should indicate one dose for adults 60 years of age and older Allowed for pregnant persons between 32 – 36 weeks of gestation (effective 10/11/2023) |
||
90679 | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use. | Adults | Benefit limits should indicate one dose for adults 60 years of age and older | ||
Rotavirus | 90680 | Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use |
Pediatric | Do not begin series in infants older than age 14 wks 6 days.
|
|
90681 | Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use |
Pediatric | Do not begin series in infants older than age 14wks 6 days.
|
||
Diphtheria, tetanus toxoids, acellular pertussis and polio inactive (DTap-IPV) | 90696 | Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use | Pediatric | For applicable age see code description. | |
90697 | Diphtheria and tetanus toxoids and acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | Pediatric | Age 6 weeks – fifth birthday | ||
Diphtheria, tetanus toxoids, acellular pertussis, haemophilus influenza B, and polio inactive (DTap-IPV/Hib) | 90698 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenzae Type b, and inactivated poliovirus vaccine (DTaP-IPV/Hib), for intramuscular use | Both | - | |
Diphtheria, tetanus, acellular pertussis (DTap) | 90700 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use | Pediatric | For applicable age see code description | |
Diphtheria and tetanus (DT) | 90702 | Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use | Pediatric | For applicable age see code description | |
Tentanus |
90703 | Tetanus toxoid adsorbed, for intramuscular use | Both | - | |
Measles, Mumps, Rubella (MMR) combination or individual | 90704 | Mumps virus vaccine, live, for subcutaneous use | Both | - | |
90705 | Measles virus vaccine, live, for subcutaneous use | Both | - | ||
90706 | Rubella virus vaccine, live, for subcutaneous use | Both | - | ||
90707 | Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use | Both | - | ||
90708 | Measles and rubella virus vaccine, live, for subcutaneous use | Both | - | ||
90710 | Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use | Both | - | ||
Polio (IPV) |
90713 | Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use | Both | - | |
Tetanus and diphtheria (Td) | 90714 | Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use | Both | For applicable age see code description. | |
Tetanus, diphtheria toxoids and acellular pertussis (Tdap) | 90715 | Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | Both | For applicable age see code description. | |
Varicella (VAR) (‘chicken pox’) |
90716 |
Varicella virus vaccine (VAR), live, for subcutaneous use | Both | - | |
Diphtheria | 90719 | Diphtheria toxoid, for intramuscular use | Both | - | |
Diptheria, tetanus and whole pertussis and Haemophilus influenza B (DTwP-Hib) | 90720 | Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Haemophilus influenzae b vaccine (DTwP-Hib), for intramuscular use | Both | - | |
Diptheria, tetanus and acellular pertussis and Haemophilus influenza B (DTaP-Hib) | 90721 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Haemophilus influenza b vaccine (DTaP/Hib), for intramuscular use | Both | - | |
Diptheria, tetanus and acellular pertussis, hep B, and polio inactive (DTaP-HepB-IPV) | 90723 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use | Both | Benefit Limit: Ages 0 – 6yrs. Ends on 7th birthday. | |
Zoster / Shingles (HZV) | 90736 | Zoster (shingles) vaccine (HZV), live, for subcutaneous injection | Adult | Benefit Limit: Age 50 years and up. | |
90750 (effective 01/01/2017) | ZOSTER (SHINGLES) VACCINE (HZV), RECOMBINANT, SUB-UNIT, ADJUVANTED, FOR INTRAMUSCULAR INJECTION | Both | Age limit 19 years and if immunodeficiency or immunosuppression exist 19-49 years. Allow for age 50 and greater. | ||
Hepatitis B |
90739 | Hepatitis B vaccine, adult dosage (2 dose schedule), for intramuscular use | Adult | For applicable age see code description. | |
90740 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use | Both | - | ||
90743 | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use | Pediatric (adolescent only) | For applicable age see code description. | ||
90744 | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use | Pediatric | For applicable age see code description. | ||
90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | Adult | For applicable age see code description. | ||
90747 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use | Both | - | ||
90748 | Hepatitis B and Haemophilus influenza b vaccine (Hib-HepB), for intramuscular use | Both | - | ||
90759 | Hepatitis B vaccine (Recombinant) Injectable Suspension, for intramuscular use | Both | - |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.
References
- http://www.cdc.gov/vaccines/acip/recs/index.html
- http://www.cdc.gov/vaccines/hcp/acip-recs/index.html
- http://www.cdc.gov/vaccines/schedules/hcp/index.html
- http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
- http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html
- http://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt
- http://www.cdc.gov/flu/protect/vaccine/vaccines.htm
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2024 Forward
10/15/2024 | Annual review, no change to policy intent. |
08/13/2024 | Interim review, adding CPT 90759 to coding section for Hepatitis B. |
06/26/2024 | Interim review, adding 90684 (effective 6/17/2024) to the coding section for pneumococcal conjugate vaccine. |
06/05/2024 | Interim review, adding 90683 (effective 05312024) to the coding section for respiratory syncytial virus vaccine. |
01/01/2024 |
NEW POLICY |